Copyright
©The Author(s) 2018.
World J Clin Oncol. Sep 14, 2018; 9(5): 110-118
Published online Sep 14, 2018. doi: 10.5306/wjco.v9.i5.110
Published online Sep 14, 2018. doi: 10.5306/wjco.v9.i5.110
Table 3 Contingency table of tumor response with FOLFIRI3-aflibercept according to prior tumor response with irinotecan [n = 35, n (%)]
| FOLFIRI3-aflibercept | ||||||
| CR/PR | SD | PD | NE | All | ||
| Prior irinotecan-based regimen | CR/PR | 5 | 3 | 7 | 0 | 15 (42.8) |
| SD | 4 | 4 | 2 | 0 | 10 (28.6) | |
| PD | 1 | 2 | 3 | 1 | 7 (20.0) | |
| NE | 2 | 0 | 1 | 0 | 3 (8.6) | |
| All | 12 (34.3) | 9 (25.7) | 13 (37.1) | 1 (2.8) | 35 | |
- Citation: Carola C, Ghiringhelli F, Kim S, André T, Barlet J, Bengrine-Lefevre L, Marijon H, Garcia-Larnicol ML, Borg C, Dainese L, Steuer N, Richa H, Benetkiewicz M, Larsen AK, Gramont A, Chibaudel B. FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer. World J Clin Oncol 2018; 9(5): 110-118
- URL: https://www.wjgnet.com/2218-4333/full/v9/i5/110.htm
- DOI: https://dx.doi.org/10.5306/wjco.v9.i5.110